Logo

FOLD

Amicus Therapeutics, Inc.

FOLD

Amicus Therapeutics, Inc. • NASDAQ
$9.93 ▼ -0.90% (-0.09)
Market Cap $3.06 B
52w High $10.57
52w Low $5.51
Dividend Yield 0%
P/E -248.25
Volume 1.24M
Outstanding Shares 308.53M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q3-2025 $169.061M ▲ $113.451M ▼ $17.306M ▲ 10.237% ▲ $0.056 ▲ $47.859M ▲
Q2-2025 $154.688M ▲ $148.945M ▲ $-24.42M ▼ -15.787% ▲ $-0.08 ▼ $-5.764M ▼
Q1-2025 $125.249M ▼ $121.503M ▲ $-21.686M ▼ -17.314% ▼ $-0.07 ▼ $-4.753M ▼
Q4-2024 $149.706M ▲ $118.899M ▲ $14.739M ▲ 9.845% ▲ $0.049 ▲ $21.933M ▲
Q3-2024 $141.517M $106.579M $-6.729M -4.755% $-0.02 $21.647M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q3-2025 $263.843M ▲ $868.811M ▲ $638.387M ▲ $230.424M ▲
Q2-2025 $230.998M ▼ $815.303M ▲ $610.999M ▲ $204.304M ▲
Q1-2025 $250.573M ▲ $789.839M ▲ $596.281M ▲ $193.558M ▼
Q4-2024 $249.946M ▲ $785.033M ▼ $590.988M ▼ $194.045M ▲
Q3-2024 $249.757M $786.557M $607.732M $178.825M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q3-2025 $17.306M ▲ $35.66M ▲ $-1.299M ▲ $-1.319M ▼ $31.851M ▲ $35.278M ▲
Q2-2025 $-24.42M ▼ $-26.526M ▼ $-5.778M ▲ $-400K ▲ $-22.717M ▲ $-28.929M ▼
Q1-2025 $-21.686M ▼ $7.758M ▲ $-32.861M ▼ $-11.7M ▼ $-31.984M ▼ $7.546M ▲
Q4-2024 $14.739M ▲ $-3.916M ▲ $-20.392M ▼ $1.097M ▼ $-20.104M ▼ $-4.204M ▲
Q3-2024 $-6.729M $-22.971M $34.272M $18.19M $24.463M $-23.327M

Five-Year Company Overview

Income Statement

Income Statement Revenue has been climbing steadily over the past five years, which is a good sign that the company’s core products are gaining traction. Gross profit has improved along with sales, suggesting the underlying business is scaling reasonably well. Operating performance has moved from meaningful losses to roughly break‑even and even slightly positive recently, showing better cost control and leverage on fixed expenses. However, the company still reports overall net losses, mainly due to costs outside pure operations (such as interest and other non‑operating items). In plain terms: the business of selling the drugs is getting close to self‑sustaining, but the company as a whole isn’t consistently profitable yet.

Balance Sheet

Balance Sheet The balance sheet shows a relatively stable asset base with a solid, though not huge, cash cushion. Debt is significant compared to the company’s size and has stayed fairly constant, which means leverage is an ongoing consideration. Equity dipped a few years ago but has since recovered, indicating gradual rebuilding of the company’s financial position as losses have narrowed. Overall, the balance sheet looks adequate for a mid‑stage biotech with commercial products, but it does carry a noticeable level of debt, so continued progress toward profitability remains important for long‑term financial resilience.

Cash Flow

Cash Flow The company is still using cash rather than generating it, but the rate of cash burn from operations has been shrinking over time. Free cash flow remains negative, yet the direction is encouraging: less cash is being consumed each year as revenues grow and costs are better managed. Capital spending is modest, so most cash outflows are tied to operating needs and development efforts rather than heavy investment in physical assets. In short, the business is not yet self‑funding, but the trend suggests it is moving closer to that point if execution continues to improve.

Competitive Edge

Competitive Edge Amicus operates in a focused niche of rare and orphan diseases, which typically have fewer competitors, strong patient loyalty, and favorable regulatory support. Its flagship drug for Fabry disease offers the convenience of an oral treatment where many rivals rely on infusions, giving a clear patient‑experience advantage. Its Pompe disease therapy combines an engineered enzyme with an oral stabilizer, aiming to improve on established treatments from large players like Sanofi and others. Strong patent protection, including a long runway for its Fabry drug in the U.S., reinforces its position. However, it still competes against well‑funded global pharma companies with broad resources, so continued differentiation and execution are essential to defend and grow share.

Innovation and R&D

Innovation and R&D The company’s innovation story is built around three pillars: pharmacological chaperones (small molecules that help misfolded enzymes function), optimized biologic drugs, and a strategic foothold in gene therapy. Its first successes, such as the Fabry and Pompe products, show an ability to turn complex science into commercial therapies that solve real patient problems. The relationship with Caritas Therapeutics allows Amicus to keep exposure to gene therapy for Fabry, Pompe, and certain neurological diseases, without shouldering all the development risk and cost. A preclinical pipeline and next‑generation approaches suggest ongoing scientific ambition, but as with all biotech R&D, there is substantial uncertainty around timelines, clinical outcomes, and eventual commercial value. Innovation is clearly a strength, but it requires continued investment and careful risk management.

Summary

Amicus has evolved from a purely development‑stage biotech into a commercial rare‑disease company with growing revenue and improving operating performance. The core business is edging toward profitability, although net income and cash flow are still negative. Its balance sheet carries meaningful debt but also enough cash and assets to support ongoing operations for now, provided progress toward sustained profitability continues. Competitively, the company benefits from a tight focus on rare diseases, differentiated products, strong patient engagement, and long‑dated patent protection, while still facing competition from large pharmaceutical firms. Its scientific platforms and ties to gene therapy create real long‑term opportunity, but also come with the typical biotech risks around clinical, regulatory, and execution outcomes. Overall, this is a company in transition from “R&D‑heavy and loss‑making” toward “commercially driven and more self‑funded,” with both promise and non‑trivial risk along that path.

NEWS

November 4, 2025 · 7:00 AM UTC

Amicus Therapeutics Announces Third Quarter 2025 Financial Results and Corporate Updates

Read more

October 31, 2025 · 7:00 AM UTC

Amicus Therapeutics to Present at Upcoming Investor Conferences in November 2025

Read more

October 23, 2025 · 7:00 AM UTC

Amicus Therapeutics to Announce Third Quarter 2025 Financial Results on November 4, 2025

Read more

September 8, 2025 · 9:00 AM UTC

New 4-Year Data for Pombiliti® (cipaglucosidase alfa-atga) + Opfolda® (miglustat) Presented at ICIEM

Read more